



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07F 9/38, 9/572, A61K 31/66	A1	(11) International Publication Number: WO 92/13864
		(43) International Publication Date: 20 August 1992 (20.08.92)

(21) International Application Number: PCT/EP92/00102

(22) International Filing Date: 20 January 1992 (20.01.92)

(30) Priority data:
MI91A000254 1 February 1991 (01.02.91) IT

(71) Applicant (for all designated States except US): ISTITUTO GENTILI S.P.A. [IT/IT]; Via Mazzini, 112, I-56100 Pisa (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROSINI, Sergio [IT/IT]; MIAN, Maurizio [IT/IT]; Via Mazzini, 112, I-56100 Pisa (IT).


(74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.

Published

With international search report.

(54) Title: ACYLAMINO-ALKYLIDEN-HYDROXY-BISPHOSPHONIC ACIDS USEFUL IN THE THERAPY OF OSTEOARTICULAR DISEASES



(I)

(57) Abstract

Hydroxydiphosphonic acids of general formula (I), a process for the preparation thereof and the use thereof in anti-inflammatory therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

Acylamino-alkyliden-hydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases.

The present invention relates to compounds of general formula (I)



5

wherein A is a $-(\text{CH}_2)_n$ group with n comprised between 1 and 10;

R is an acyl residue from a known anti-inflammatory compound belonging in the class of salicylic, arylacetic, arylpropionic, anthranilic, 4,5-dihydroxy- or 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-carboxylic, nicotinic acids.

Examples of known anti-inflammatory acids, the acyl residues of which form the R group, as defined in formula (I), are reported hereinbelow:

salicylic acids: salicylic acid, acetylsalicylic acid, 5-aminosalicylic acid, diflunisal, fendosal;

arylacetic acids: acemetacin, alclofenac, amfenac, ben-zadac, bufexamac, bumadizone, cinmetacin, clidanac, clometacin, clopirac, diclofenac, etodolac, fenclofenac, indobufen, indometacin, methiazinic acid, sulindac, tolmetin, zomepirac;

propionic acids: alminoprofen, benoxaprofen, bucloxic acid, carprofen, flurbiprofen, ibuprofen, ketoprofen, loxoprofen, naproxen, oxaprozin, protizinic acid, piroxicam, piroxicam, pranoprofen, suprofen, thiaprofe-

nic acid;

anthranilic acids: flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid, lobenzarit, tolfenamic acid;

5 4,5-dihydroxy- or 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acids: diacerhein, thio-rhein.

Particularly preferred are the compounds of formula (I) wherein R is 2-acetoxybenzoyl, the residues
10 from diflunisal, ibufenac, ibuprofen, naproxen, indometacin, diacerhein.

Most preferred compounds are those in which n is 3 or 5.

In case the residue R contains one or more chiral
15 carbon atoms, the invention comprises the single enantiomers and the mixtures of racemates and of diastereoisomers thereof.

The invention also relates to the diphosphonic acid salts, the esters of both the phosphonic groups
20 and the hydroxy group, with the proviso that they are pharmaceutically acceptable.

The compounds of formula (I) derive from the condensation of known anti-inflammatory compounds with known ω -aminoalkylene-1-hydroxy-1,1-diphosphonic acid
25 derivatives already used in therapy due to their inhibiting action on bone resorption and antiurolithiasic action.

ω -Aminoalkylene-1-hydroxy-1,1-diphosphonic acids are described in Italian Patent Applications N.
30 22047A/88 and 1274A/89 and in German Patent Applications N. DE-OS 2,534,391 and DE-OS 3,540,150.


Alkyl-1-hydroxy-1,1-diphosphonic acid derivatives condensed with anti-inflammatory residues through a C-C bond are known from EP-A-84822.

5 The compounds of the invention, on the contrary, are characterized by an amido bond between the amino group of the ω -aminoalkylenedihydroxydiphosphonic acid and the carboxy group of the anti-inflammatory compound.

Contrarily to what could be assumed, the pharmacological properties of the compounds of formula (I) are not those typical of "pro-drugs" which can release "in vivo" the two components which independently carry on their therapeutical activities.

15 In fact, it has surprisingly been found that compounds (I) have a far higher anti-inflammatory activity than the one which could be assigned to the "in vivo" release of a known RCOOH pharmacologically active acid. This is even more surprising in that the aminoalkylenedihydroxydiphosphonic component is completely devoid of anti-inflammatory activity.

20 Compounds of formula (I) are prepared by reacting a compound of formula (II)



25

wherein A has the above mentioned meaning, with a compound of formula RCOOH, wherein R is as defined above, or with a reactive derivative thereof (chloride, anhydride, imidazolid etc.).

30

The reaction is preferably carried out in an aqueous medium in the presence of alkali, using a

reactive derivative of the carboxy group of the R molecule, such as the acid chloride.

The advantageous properties of the compounds of the invention make them useful in the therapy of muscle-skeletal apparatus disorders.

Therefore, the compounds of the invention will be used for the preparation of pharmaceutical compositions in admixture with suitable excipients and/or other drugs which can adjuvate the therapeutic action.

Examples of said pharmaceutical compositions comprise both solid and liquid oral formulations, optionally in sustained-release or gastro-resistant forms, injectable formulations, optionally in depot forms, suppositories and topical forms.

The posology will be determined according to the pathology and patient's conditions (age, sex, weight) and the clinician's prescriptions. Dosage forms could be unit forms containing 2 to 500 mg of the active ingredient per unit dose.

The following examples further illustrate the invention.

EXAMPLE 1

[4-(2-Acetoxybenzoyl)-amino-1-hydroxybutylidene]-diphosphonic acid

3.18 g (9.8 mmol) of sodium trihydrogen 4-amino-1-hydroxybutylidenediphosphonate trihydrate are added in 30 ml of water to 1.8 g (45 mmol) of sodium hydroxide, 100 mg of p-dimethylaminopyridine and 200 mg of tetrahexylammonium iodide. The resulting solution is cooled to 0°C, and added with 2.03 g (10.2 mmol) of 2-acetoxybenzoic acid chloride dissolved in 10 ml of

diethyl ether. The reaction mixture is stirred for 2 hours at room temperature, then it is extracted with ethyl ether and the aqueous solution is acidified with concentrated HCl under stirring, with cooling. [4-(2-Hydroxybenzoyl)-amino-1-hydroxybutylidene]-diphosphonic acid precipitates, which is filtered, washed and dried at 70°C and transformed into the title product by means of acetylation with acetic anhydride.

M.P. (dec.) > 150°C.

10 E.A. for $C_{13}H_{19}NO_{10}P_2$

	theoretic %	found %
C	37.96	38.04
H	4.65	4.69
N	3.40	3.45

15 I.R. and 1H N.M.R. in conformity.

EXAMPLE 2

[6-(2-Acetoxybenzoyl)-amino-1-hydroxyhexylidene]-diphosphonic acid

The procedure of example 1 is followed, but using 20 3.45 g (9.8 mmoles) of sodium trihydrogen 6-amino-1-hydroxyhexylidenediphosphonate trihydrate.

[6-(2-Hydroxybenzoyl)-amino-1-hydroxyhexylidene]-diphosphonic acid precipitates. The procedure of example 1 is repeated, to obtain the title product, having 25 the following characteristics:

M.P. (dec.) > 150°C

E.A. for $C_{15}H_{23}NO_{10}P_2$

	theoretic %	found %
30 C	41.00	40.94
H	5.27	5.23
N	3.18	3.24

I.R. and ¹H N.M.R. in conformity.

EXAMPLE 3

[4-[5-(2,4-Difluorophenyl)-2-hydroxybenzoyl]-amino-1-hydroxybutylidene]-diphosphonic acid

5 The procedure of example 1 is repeated, using 3.18 g (10.2 mmoles) of 5-(2,4-difluorophenyl)-2-acetoxybenzoic acid chloride.

After acidification with concentrated HCl, the title product precipitates, having the following characteristics:

M.P. (dec) > 150°C

E.A. for C₁₇H₁₉F₂NO₉P₂

	theoretic %	found %
C	42.41	42.36
15 H	3.97	3.94
N	2.90	2.98

I.R. and ¹H N.M.R. in conformity.

Analogously to the above examples, the following compounds have been prepared:

20

EXAMPLE 4

[6-[5-(2,4-Difluorophenyl)-2-hydroxybenzoyl]-amino-1-hydroxyhexylidene]-diphosphonic acid

M.P. (dec) > 150°C

E.A. for C₁₉H₂₃F₂NO₉P₂

	theoretic %	found %
25 C	44.80	44.85
H	4.55	4.58
N	2.74	2.80

I.R. and ¹H N.M.R. in conformity.

30

EXAMPLE 5

[4-(4-Isobutylphenyl)-acetylamino-1-hydroxybutylidene]-

diphosphonic acid

M.P. (dec) > 150°C

E.A. for $C_{16}H_{27}NO_8P_2$

	theoretic %	found %
5 C	45.38	45.44
H	6.42	6.47
N	3.30	3.36

I.R. and 1H N.M.R. in conformity.EXAMPLE 610 [6-(4-Isobutylphenyl)-acetylamino-1-hydroxyhexylidene]-
diphosphonic acid

M.P. (dec) > 150°C

E.A. for $C_{18}H_{31}NO_8P_2$

	theoretic %	found %
15 C	47.88	47.93
H	6.12	6.14
N	3.10	3.18

EXAMPLE 720 [4-[2-(4-Isobutylphenyl)-propionyl]-amino-1-hydroxybu-
tylidene]-diphosphonic acid

M.P. (dec) > 150°C

E.A. for $C_{17}H_{29}NO_8P_2$

	theoretic %	found %
C	46.67	46.61
25 H	6.68	6.65
N	3.20	3.27

I.R. and 1H N.M.R. in conformity.EXAMPLE 830 [6-[2-(4-Isobutylphenyl)-propionyl]-amino-1-hydroxyhe-
xylidene]-diphosphonic acid

M.P. (dec) > 150°C

E.A. for $C_{19}H_{33}NO_8P_2$

theoretic %

found %

C 49.02

48.96

H 7.14

7.09

5 N 3.00

2.95

I.R. and 1N.M.R. in conformity.

EXAMPLE 9[4-[2-(6-Methoxynaphthyl)-propionyl]-amino-1-hydroxybutylidene]]-diphosphonic acid

10 M.P. (dec) > 150°C

E.A. for $C_{18}H_{25}NO_9P_2$

theoretic %

found %

C 46.85

46.80

H 5.46

5.47

15 N 3.03

3.00

I.R. and 1H N.M.R. in conformity.

EXAMPLE 10[6-[2-(6-Methoxynaphthyl)-propionyl]-amino-1-hydroxyhexylidene]-diphosphonic acid

20 M.P. (dec) > 150°C

E.A. for $C_{20}H_{29}NO_9P_2$

theoretic %

found %

C 49.07

49.02

H 5.97

5.96

25 N 2.86

2.90

EXAMPLE 11[4-[1-(4-Chlorobenzoyl)-2-methyl-5-methoxy-2-indolyl]-acetyl-amino-1-hydroxybutylidene]-diphosphonic acid

M.P. (dec) 150°C

30 E.A. for $C_{23}H_{27}ClN_2O_{10}P_2$

	theoretic %	found %
C	46.90	46.99
H	4.62	4.66
N	4.75	4.68

5 I.R. and ¹H N.M.R. in conformity.

EXAMPLE 12

[6-[1-(4-Chlorobenzoyl)-2-methyl-5-methoxy-2-indolyl]-acetyl-amino-1-hydroxyhexylidene]-diphosphonic acid

M.P. (dec) > 150°C

10 E.A. for C₂₅H₃₁ClN₂O₁₀P₂

	theoretic %	found %
C	48.66	-
H	5.06	-
N	4.53	-

15 I.R. and ¹H N.M.R. in conformity.

EXAMPLE 13

Carrageenin oedema in rat

Used substances:

Carrageenin (control -)

20 Carrageenin + Ibuprofen (11 and 5.5 mg/kg)

Carrageenin + compound of example 8 (Br-Aex) (25.0 and 12.5 mg/kg)

Carrageenin + compound of example 7 (Br-Ab) (25.0 and 12.5 mg/kg)

25 Note: Ibuprofen doses are equimolar to the corresponding Br-Ab and Br-Aex doses.

Used animals:

S.D. male rats weighing 160 - 180 g

Test groups:

30 1) Control - (Carrageenin only)

2) Ibuprofen 11.0 mg/kg

- 3) Ibuprofen 5.5 mg/kg
4) Br-Ab 25.0 mg/kg
5) Br-Ab 12.5 mg/kg
6) Br-Aex 25.0 mg/kg
5 7) Br-Aex 12.5 mg/kg

Each group consisted of 5 males, trying to obtain the most homogeneous total weight for each group. The animals were inoculated subcutaneously with the test solutions homogenized in 5% gum Arabic which had been
10 sterilized by filtration with "Acrodisc" Gelman with 0.45 µl pores.

After 1 hour the animals were slightly anaesthetized with 0.1 ml of 1% carrageenin in sterile saline. Carrageenin was kept under stirring by means of a ma-
15 gnetic stirred, to make it as homogeneous as possible.

At the same time, the basal paw volumes were determined by means of a plethysmograph, so as to make possible to repeat the measurements in the most reliable way in the subsequent hours.

20 2 Hours after carrageenin inoculation, the measure of paw volumes was determined (2nd hour). Subsequently, said measurement was effected at the 4th and 6th hours from inoculation. After that, the % protection was calculated by means of the following formula:

25

$$\frac{\text{Increase in paw volume of the treated group}}{\text{Increase of paw volume in control group}} \times 100 = A$$
$$100 - A = \% \text{ Protection}$$

Table 1 (% Protection)

	Product	% Protection 2 nd hour	% Protection 4 th hour	% Protection 6 th hour
5	Ibuprofen (11.0 mg/kg)	21%	25%	28%
	Ibuprofen (5.5 mg/kg)	18%	3%	4%
	Br-Ab (25.0 mg/kg)	68%	57%	38%
10	Br-Ab (12.5 mg/kg)	31%	28%	30%
	Br-Ax (25.0 mg/kg)	42%	21%	56%
15	Br-Ax (12.5 mg/kg)	41%	36%	48%

The obtained results show that all of the compounds of the invention give a higher protection than one of Ibuprofen; moreover, pharmacological differences exist among the compounds of the invention due to the methylene portion length (A in general formula).

EXAMPLE 14


Male rats weighing about 200 mg are thyroparathyroidectomized under Nembutal anaesthesia. The animals are treated with thyroxine on alternate days during all the test. 7 Days after surgery, blood is withdrawn by means of intracardiac puncture and Ca is determined on plasma. The animals with a Ca plasma content higher than 2 mM are excluded from the test, the others are treated with the compounds under test and with retinoid which is administered subcutaneously for 3 consecutive days. 24 Hours after the last administration, animals are killed and blood is recovered to determine Ca again.

Table 2

EFFECT OF BR-AB AND BR-AX DERIVATIVES ON BONE CALCIUM LOSS INDUCED BY RETINOID IN RAT			
5	Compound	Plasmatic Ca increase after retinoid adm. (mmol/lt)	% inhibition
	Controls	1.11 ± 0.03	-
	AHBuBP	0.29 ± 0.2	73.9
	BRU-AB	0.62 ± 0.03	44.1
10	BRU-AX	0.75 ± 0.17	32.4

CLAIMS

1. Compounds of general formula (I)



wherein A is a $-(\text{CH}_2)_n$ group with n comprised between 1 and 10;

R is an acyl residue from a known anti-inflammatory compound belonging in the class of salicylic, arylacetic, arylpropionic, anthranilic, 4,5-dihydroxy- or 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-carboxylic, nicotinic acids.

2. Compounds according to claim 1, wherein A is as defined above and R is one of the acyl residues from the following compounds: salicylic acid, acetylsalicylic acid, 5-aminosalicylic acid, diflunisal, fendosal, acemetacin, alclofenac, amfenac, benzydac, bufexamac, bumadizone, cinmetacin, clidanac, clometacin, clopirac, diclofenac, etodolac, fenclofenac, indobufen, indometacin, methiazinic acid, sulindac, tolmetin, zomepirac, alminoprofen, benoxaprofen, bucloxic acid, carprofen, flurbiprofen, ibuprofen, ketoprofen, loxoprofen, naproxen, oxaprozin, protizinic acid, pineprofen, piroprofen, pranoprofen, suprofen, thiaprofenic acid, flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid, lobenzarit, tolfenamic acid, diacerhein, thiorhein.

3. Compounds according to claims 1-2, wherein A is as defined above, R is 2-acetoxybenzoyl, the residues from diflunisal, ibufenac, ibuprofen; naproxen; indometacin;

diacerhein.

4. Compounds according to claims 1-3, wherein A is $-(CH_2)_5-$ or $-(CH_2)_3-$, and R is as defined in claim 3.

5. A process for the preparation of compounds of formula I, characterized in that a compound of formula $R-COOH$ is reacted with a compound of formula (II)



6. A process for the preparation of compounds of formula I according to claim 4, characterized in that $R-COOH$ acid chloride is reacted with compound of formula (II)



7. The use of compounds of claims 1-4 as therapeutic agents.


8. Pharmaceutical compositions containing as the active ingredients the compounds of claims 1-3 in admixture with pharmaceutically acceptable carriers and diluents.

9. The use of compounds of claims 1-3, for the preparation of a medicament for the treatment of osteoarticular and connective tissue disorders.

INTERNATIONAL SEARCH REPORT

PCT/EP 92/00102

International Application

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07F9/38; C07F9/572; A61K31/66		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07F	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP,A,0 084 822 (SCHERING AG) 3 August 1983 cited in the application see the whole document ---	1,7,8,9
Y	EP,A,0 197 478 (BOEHRINGER MANNHEIM GMBH) 15 October 1986 ---	1,7,8,9
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
25 MARCH 1992	31. 03. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	BESLIER L.M. 	

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. EP 9200102
SA 55304

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 25/03/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0084822	03-08-83	DE-A- 3203308	28-07-83
		DE-A- 3243917	24-05-84
		AU-B- 561542	14-05-87
		AU-A- 1074283	04-08-83
		CA-A- 1224459	21-07-87
		GB-A- 2113688	10-08-83
		JP-A- 58174393	13-10-83
		US-A- 4503049	05-03-85
EP-A-0197478	15-10-86	DE-A- 3512536	16-10-86
		JP-A- 61236788	22-10-86
		US-A- 4666895	19-05-87